STA
GILD icon

Summit Trail Advisors’s Gilead Sciences GILD Stock Holding History

Summit Trail Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.55M Buy
43,955
+124
+0.3% +$16.3K 0.07% 170
2026
Q1 		$6.11M Buy
43,831
+7,917
+22% +$1.11M 0.09% 127
2025
Q4 		$4.41M Sell
35,914
-6,159
-15% -$748K 0.08% 150
2025
Q3 		$4.67M Buy
42,073
+2,053
+5% +$233K 0.06% 153
2025
Q2 		$4.44M Buy
+40,020
New +$4.26M 0.08% 135
2024
Q4 		– Sell
-20,884
Closed -$1.75M – 527
2024
Q3 		$1.75M Buy
20,884
+3,779
+22% +$288K 0.04% 177
2024
Q2 		$1.17M Buy
17,105
+4,683
+38% +$313K 0.03% 216
2024
Q1 		$910K Buy
12,422
+65
+0.5% +$5K 0.02% 230
2023
Q4 		$1M Sell
12,357
-92
-0.7% -$7.16K 0.03% 178
2023
Q3 		$933K Buy
12,449
+444
+4% +$34.2K 0.03% 175
2023
Q2 		$925K Buy
12,005
+3,090
+35% +$246K 0.03% 182
2023
Q1 		$740K Buy
8,915
+3,000
+51% +$248K 0.03% 166
2022
Q4 		$508K Sell
5,915
-810
-12% -$64.1K 0.02% 184
2022
Q3 		$415K Buy
+6,725
New +$424K 0.02% 206
2021
Q4 		– Sell
-3,420
Closed -$239K – 303
2021
Q3 		$239K Buy
3,420
+283
+9% +$19.9K 0.02% 230
2021
Q2 		$216K Sell
3,137
-63
-2% -$4.21K 0.02% 200
2021
Q1 		$207K Sell
3,200
-353
-10% -$22.8K 0.02% 179
2020
Q4 		$207K Buy
+3,553
New +$214K 0.03% 176
2020
Q3 		– Sell
-2,658
Closed -$204K – 219
2020
Q2 		$204K Buy
+2,658
New +$204K 0.04% 151
2018
Q2 		– Sell
-7,808
Closed -$348K – 546
2018
Q1 		$348K Buy
7,808
+2,265
+41% +$180K 0.06% 246
2017
Q4 		$439K Buy
+5,543
New +$421K 0.06% 250

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Summit Trail Advisors's GILD Position: Q2 2026 in Review

Summit Trail Advisors increased its Gilead Sciences (GILD) stake by 0.28% in Q2 2026, buying an estimated $16.3K and bringing the position to 43,955 shares worth $5.55M. The position accounts for 0.07% of the portfolio, ranked #170.

Summit Trail Advisors first reported a position in GILD in Q4 2017 and has held it in 21 quarters since. The position peaked at $6.11M in Q1 2026. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Summit Trail Advisors held 43,955 shares of Gilead Sciences worth $5.55M as of Q2 2026.
  • Summit Trail Advisors bought 124 Gilead Sciences shares in Q2 2026, an estimated $16.3K.
  • Gilead Sciences made up 0.07% of Summit Trail Advisors's portfolio in Q2 2026, its #170 holding.
  • Summit Trail Advisors first reported a position in Gilead Sciences in Q4 2017 and has held it in 21 quarters since.
  • Summit Trail Advisors's Gilead Sciences position peaked at $6.11M in Q1 2026.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.